ERBB3 and breast neoplasm: The findings from the current study are in agreement with the existing literature, which suggests a high level of PI3K signaling in a subset of breast tumors and that HER2/HER3 is a strong driver of oncogenic HER2 signaling through PI3K activation in this subset [12–15].